李日明 廖湘晖 吴丽娟 刘祥东

    【摘要】 目的：探讨质子泵抑制剂联合XELOX辅助化疗治疗进展期结肠癌的效果。方法：选取2014年5月-2015年5月本院收治的进展期结肠癌患者80例，采用信封法将其分为对照组与观察组，每组40例。两组均进行手术治疗，对照组术后采用XELOX辅助化疗，观察组术后采用质子泵抑制剂联合XELOX辅助化疗。比较两组不同TNM分期及V-ATPase表达情况的1、3、5年无病生存率(DFS)。结果：观察组与对照组V-ATPase表达阳性率分别为67.5%与62.5%，两组比较差异无统计学意义(P>0.05)。两组中ⅡB期患者1、3、5年DFS比较，差异均无统计学意义(P>0.05)。观察组中Ⅲ期患者1、3年DFS高于对照组(P0.05)。观察组中V-ATPase表达阳性患者1、3年DFS均高于对照组(P0.05). There were no significant differences in 1-year， 3-yaer， 5-year DFS of stage ⅡB patients between the two groups (P>0.05). 1-year and 3-year DFS of stage Ⅲ patients in the observation group were higher than those in the control group (P0.05). The 1-yaer and 3-year DFS of patients with positive expression of V-ATPase in the observation group were higher than those in the control group (P0.05) ......